Tobacco use, oral health, and risk of Parkinson's disease

American Journal of Epidemiology

Volumn 185, Issue 7, 2017, Pages 538-545

  Liu, Zhiwei ^a   Roosaar, Ann ^b   Axéll, Tony ^b   Ye, Weimin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HALMSTAD HOSPITAL   (Sweden)

Author keywords

Cohort studies; Oral health; Parkinson's disease; Smoking; Snus; Tobacco

Indexed keywords

CHEMICAL SUBSTANCE; COHORT ANALYSIS; CONFIDENCE INTERVAL; HEALTH RISK; HEALTH SURVEY; LESION; NERVOUS SYSTEM DISORDER; ORAL HEALTH; SMOKING;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MOUTH LESION; PARKINSON DISEASE; RISK ASSESSMENT; SNUS; SWEDEN; THRUSH; TOBACCO USE; TOOTH PLAQUE; ADOLESCENT; ADVERSE EFFECTS; AGE; DENTAL PLAQUE; HEALTH; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; SMOKELESS TOBACCO; TOOTH LOSS; YOUNG ADULT;

SWEDEN; UPPSALA [SWEDEN];

CANDIDA; NICOTIANA TABACUM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DENTAL PLAQUE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORAL HEALTH; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SWEDEN; TOBACCO, SMOKELESS; TOOTH LOSS; YOUNG ADULT;

EID: 85019454049     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kww146     Document Type: Article

References (50)

1. Ritz B, Lee PC, Lassen C.F., et al. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014; 83(16):1396-1402.
2. Wirdefeldt K, Adami HO, Cole P, et al Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26(suppl 1):S1-S58.
3. Hernán M.A., Takkouche B, Caamaño-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002; 52(3):276-284.
4. Allam MF, Campbell MJ, Hofman A, et al Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord. 2004; 19(6):614-621.
5. Ritz B, Ascherio A, Checkoway H., et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007; 64(7):990-997.
6. Das SK, Misra AK, Ray B.K., et al. Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based study. Neurology. 2010; 75(15):1362-1369.
7. Hong DP, Fink AL, Uversky VN Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta. 2009; 1794(2):282-290.
8. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. NEng JMed. 1988; 319(20):1318-1330.
9. Benedetti MD, Bower JH, Maraganore D.M., et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology. 2000; 55(9): 1350-1358.
10. O'Reilly E.J., McCullough ML, Chao A, et al Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord. 2005; 20(10):1383-1384.
11. Feldman AL, Johansson AL, Gatz M, et al Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology. 2012; 38(3): 186-193.
12. Beyer MK, Herlofson K, Arsland D., et al. Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand. 2001; 103(1):7-11.
13. Fall PA, Saleh A, Fredrickson M., et al. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord. 2003; 18(11):1312-1316.
14. Reale M, Iarlori C, Thomas A., et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2009; 23(1):55-63.
15. Lindqvist D, Kaufman E, Brundin L., et al. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One. 2012; 7(10): e47387.
16. Stypuła G., Kunert-Radek J, Stepien H., et al. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation. 1996; 3(2-3):131-134.
17. Dobbs RJ, Charlett A, Purkiss A.G., et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999; 100(1):34-41.
18. Chen H, O'Reilly EJ, Schwarzschild MA, et al Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008; 167(1):90-95.
19. Gao HM, Jiang J, Wilson B., et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. JNeurochem. 2002; 81(6):1285-1297.
20. Roosaar A, Johansson AL, Sandborgh-Englund G, et al. A long-term follow-up study on the natural course of snus-induced lesions among Swedish snus users. Int J Cancer. 2006; 119(2): 392-397.
21. Axéll T., Mörnstad H, Sundström B. The relation of the clinical picture to the histopathology of snuff dipper's lesions in a Swedish population. J Oral Pathol. 1976; 5(4):229-236.
22. Kowolik MJ, Dowsett SA, Rodriguez J, et al Systemic neutrophil response resulting from dental plaque accumulation. J Periodontol. 2001; 72(2):146-151.
23. Noack B, Genco RJ, Trevisan M, et al Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol. 2001; 72(9):1221-1227.
24. Margolis KL, Manson JE, Greenland P, et al Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med. 2005; 165(5):500-508.
25. Noble JM, Scarmeas N, Papapanou PN Poor oral health as a chronic, potentially modifiable dementia risk factor: review of the literature. Curr Neurol Neurosci Rep. 2013; 13(10): 384.
26. Kisely S, Baghaie H, Lalloo R., et al. A systematic review and meta-analysis of the association between poor oral health and severe mental illness. Psychosom Med. 2015; 77(1):83-92.
27. Axéll T. A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Revy Suppl. 1976; 36:1-103.
28. Roosaar A, Johansson AL, Sandborgh-Englund G, et al. Cancer and mortality among users and nonusers of snus. Int J Cancer. 2008; 123(1):168-173.
29. Huang J, Roosaar A, Axéll T, et al. A prospective cohort study on poor oral hygiene and pancreatic cancer risk. Int J Cancer. 2016; 138(2):340-347.
30. Ramfjord SP. The Periodontal Disease Index (PDI). J Periodontol. 1967; 38(6)602-610.
31. Ludvigsson JF, Otterblad-Olausson P, Pettersson B.U., et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-667.
32. Pencina MJ, Larson MG, D'Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med. 2007; 26(6):1343-1359.
33. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81(3):515-526.
34. Yang F, Trolle Lagerros Y, Bellocco R, et al Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain. 2015; 138(2):269-275.
35. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord. 2008; 23(13):1799-1807.
36. Holm H, Jarvis MJ, Russell M.A., et al. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology (Berl). 1992; 108(4):507-511.
37. Chen H, Huang X, Guo X., et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010; 74(11):878-884.
38. Kenborg L, Lassen CF, Ritz B, et al Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. Am J Epidemiol. 2015; 181(10):808-816.
39. Golbe LI, Cody RA, Duvoisin RC Smoking and Parkinson's disease. Search for a dose-response relationship. Arch Neurol. 1986; 43(8):774-778.
40. Shahi GS, Moochhala SM Smoking and Parkinson's disease - a new perspective. Rev Environ Health. 1991; 9(3):123-136.
41. Riggs JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharmacol. 1992; 15(2):88-99.
42. Morens DM, Grandinetti A, Reed D., et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 1995; 45(6):1041-1051.
43. Fratiglioni L, Wang HX Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res. 2000; 113(1-2):117-120.
44. Hershey LA, Perlmutter JS Smoking and Parkinson disease: where there is smoke there may not be fire. Neurology. 2014; 83(16):1392-1393.
45. Wirdefeldt K, Gatz M, Pawitan Y., et al. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol. 2005; 57(1):27-33.
46. Mellick GD, Gartner CE, Silburn P.A., et al. Passive smoking and Parkinson disease. Neurology. 2006; 67(1):179-180.
47. Rodu B, Stegmayr B, Nasic S., et al. Evolving patterns of tobacco use in northern Sweden. J Intern Med. 2003; 253(6): 660-665.
48. Furberg H, Lichtenstein P, Pedersen N.L., et al. Cigarettes and oral snuff use in Sweden: prevalence and transitions. Addiction. 2006; 101(10):1509-1515.
49. Lundqvist G, Sandström H, Ohman A., et al. Patterns of tobacco use: a 10-year follow-up study of smoking and snus habits in a middle-aged Swedish population. Scand J Public Health. 2009; 37(2):161-167.
50. Schrag A, Horsfall L, Walters K., et al. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 2015; 14(1):57-64.